Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M&A Trends: The Growing Indian Appetite

Executive Summary

A recent round table on pharma industry trends has highlighted the hunger of cash-rich Indian firms for acquiring companies with niche portfolios in regulated markets including the US. Innovator companies shedding their generic units also present significant opportunities for Indian firms. Both trends are expected to build amid apparent Indian interest in the Teva-Allergan divestiture in Europe.

You may also be interested in...



Lupin Buys Shionogi Brands As Japan Market Opens To Indian Firms

Kyowa, the Japanese arm of Indian major Lupin, is buying a basket of mature products including CNS drugs Rhythmy and Resmit from Shionogi. As innovator companies seek to shed older products in Japan, generic firms, especially Indian ones, are taking advantage to expand in the world's second largest pharmaceutical market.

Allergan's UK Generics Business Up For Sale Under EC Merger Condition

The European Commission has approved the proposed $40.5bn acquisition of the generics business of Allergan (the company formerly known as Actavis) by Teva, subject to a number of significant conditions, including the divestment of the majority of Allergan Generics' business in the UK and Ireland.

Buzzing Indian M&A/IPO Counter In 2016?

2016 could see an uptick in M&A deal flow in India and more than half a dozen healthcare/pharma firms may consider going public, buoyed by a clutch of successful recent IPOs, according to experts in the deal advisory/private equity space.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel